Jump to content

Spanish developed vaccine HIPRA, contracted by Vietnam pharmaceutical company

Recommended Posts


Spain gets order from Vietnam company for new vaccine.


Saigoneer reports that T&T Pharma, a Vietnamese pharmaceutical company, has signed a contract for 50 million doses of HIPRA, a COVID-19 vaccine currently undergoing trials in Spain. 



HIPRA factoy in Spain (File photo)


The vaccine, developed by HYPRA Human Health S.L.U., is a recombinant protein vaccine and can also be stored at higher temperatures than the likes of the Pfizer vaccine, which requires ultra-cold storage. 


The final trial phase of HIPRA began last month and is scheduled for completion in October, after which production would begin. The company hopes to produce 75 million doses by the end of this year, and over 600 million in 2022. According to the news source, trials thus far show that HIPRA is effective against the Delta variant.



HIPRA research dept. (File photo)


It is not clear when the doses purchased by T&T Pharma would be available. The deal is valued at US$444 million. Negotiations took place during a visit to Helsinki by Vương Đình Huệ, the National Assembly Chairman, that also saw several other pandemic-related transactions.


Slovakia donated 100,000 AstraZeneca vaccine doses, while the French company NG Biotech donated 1 million test kits. T&T Pharma also signed deals with several German companies for technology transfer and production related to COVID-19 test kits.


To date, Vietnam has administered nearly 25 million Covid vaccine doses. In total, 5.8% of the country's 97 million people are fully vaccinated.




Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
  • Recently Browsing   0 members

    No registered users viewing this page.

  • Create New...